

Published in final edited form as:

*Nat Rev Cancer*. ; 11(7): 512–522. doi:10.1038/nrc3080.

## The physics of cancer: the role of physical interactions and mechanical forces in metastasis

Denis Wirtz, Konstantinos Konstantopoulos, and Peter C. Searson

The authors are at the Departments of Materials Science and Engineering, Chemical and Biomolecular Engineering and Oncology, the Institute for Nanobiotechnology, Johns Hopkins Center of Cancer Nanotechnology Excellence, Johns Hopkins Physical Sciences in Oncology Center, Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, USA. wirtz@jhu.edu; kk@jhu.edu; searson@jhu.edu

### Abstract



Metastasis is a complex, multistep process responsible for >90% of cancer-related deaths. In addition to genetic and external environmental factors, the physical interactions of cancer cells with their microenvironment, as well as their modulation by mechanical forces, are key determinants of the metastatic process. We reconstruct the metastatic process and describe the importance of key physical and mechanical processes at each step of the cascade. The emerging insight into these physical interactions may help to solve some long-standing questions in disease progression and may lead to new approaches to developing cancer diagnostics and therapies.

In the series of steps that comprise the metastatic process, cancer cells migrate or flow through vastly different microenvironments, including the stroma, the blood vessel endothelium, the vascular system and the tissue at a secondary site<sup>1,2</sup> (FIG. 1). The ability to successfully negotiate each of these steps and advance towards the formation and growth of a secondary tumour is dependent, in part, on the physical interactions and mechanical forces between cancer cells and the microenvironment. For example, the physical interactions between a cell and the extracellular matrix — the collagen-rich scaffold on which it grows — have a key role in allowing cells to migrate from a tumour to nearby blood vessels. During intravasation and extravasation, cells must undergo large elastic deformations to penetrate endothelial cell-cell junctions. In the vascular system, the interplay between cell velocity and adhesion influences the binding of cancer cells to blood vessel walls and hence the location of sites where a secondary tumour can form and grow. A clearer understanding of the role of physical interactions and mechanical forces, and their interplay with biochemical changes, will provide new and important insights into the progression of cancer and may provide the basis for new therapeutic approaches.

### Physical interactions in invasion

Following the growth of a primary tumour, the combination of continued tumour proliferation, angiogenesis, accumulated genetic transformations and activation of complex signalling pathways trigger the metastatic cascade (FIG. 2). In particular, the detachment of carcinoma cells from the epithelium and the subsequent invasion of the underlying stroma resembles, at both the cellular and molecular levels, the well-characterized epithelial-to-mesenchymal transition (EMT) in embryogenesis<sup>3</sup>. The role of EMT in cancer metastasis is

being actively explored<sup>4,5</sup>. Critical to EMT is the loss of E-cadherin (an intercellular adhesion molecule) and cytokeratins, which leads to dramatic changes in the physical and mechanical properties of cells: specifically, reduced intercellular adhesion and a morphological change from cuboidal epithelial to mesenchymal<sup>6</sup>. One consequence of these changes is detachment from the primary tumour and the acquisition of a motile phenotype<sup>5</sup>. These cells also begin to express matrix metalloproteinases (MMPs) on their surface, which promote the digestion of the laminin- and collagen IV-rich basement membrane<sup>7</sup>. After leaving the tumour microenvironment, motile tumour cells encounter the architecturally complex extracellular matrix (ECM), which is rich in collagen I and fibronectin<sup>8</sup> (BOX 1). In the vicinity of a mammary tumour, the matrix is often stiffer than in normal tissue owing to enhanced collagen deposition<sup>9</sup> and lysyl-oxidase-mediated crosslinking of the collagen fibres by tumour-associated fibroblasts<sup>10</sup>. Collagen crosslinking enhances integrin signalling as well as the bundling of individual fibres<sup>11</sup>. Such changes in the physicochemical properties of the matrix can enhance cell proliferation and invasion in a positive feedback loop<sup>9</sup>. Whether stiffening of the stromal matrix occurs in other solid tumours, besides mammary tumours, remains to be determined. However, despite recent technological advances (TABLE 1), remarkably little is known about the molecular and physical mechanisms that drive motile cancer cells away from primary tumour and into the stromal space, especially at the subcellular level.

### Motility in three dimensions

Much of what we have learned about the physical and molecular mechanisms driving normal and cancer cell motility has come from *in vitro* studies using two-dimensional (2D) substrates<sup>12-14</sup>. However, the dimensionality of the system used to study cancer invasion can have a key role in dictating the mode of cell migration. This is not entirely surprising as the three-dimensional (3D) microenvironment of the ECM *in vivo* is characterized by many features, including the pore size and fibre orientation, features that are not found in conventional ECM-coated 2D substrates<sup>15</sup>. In turn, many features that are thought to be crucial for 2D motility, such as focal adhesions, stress fibres, wide lamellipodia and lamella, multiple filopodial protrusions at the leading edge and apical polarization, are either drastically reduced in size or entirely missing from motile carcinoma or sarcoma cells in a 3D matrix<sup>16-20</sup>. Similarly, several cellular features that are important in 3D cell motility have little or no role in 2D cell motility, including nuclear deformation, MMP production and major reorganization of the ECM.

Recent work suggests that focal adhesions, composed of clustered integrins that physically and dynamically connect the cellular actin network to ECM fibres on 2D substrates, are altered when cells are embedded inside a 3D matrix<sup>16</sup>. Focal adhesions, which are readily visible by microscopy in human breast cancer cells, colon carcinoma cells and fibrosarcoma cells plated on 2D substrates, rapidly decrease both in size and number as a function of the distance between the cells in the matrix and the substrate that supports the matrix.

The absence of prominent focal adhesions and the associated reduction and relocalization of stress fibres that join these focal adhesions is in large part due to the 3D architecture of the ECM. In general, a cell is much larger than the diameter of the fibres of the ECM, which are typically on the order of 100 nm. Therefore, from a cellular perspective, the collagen fibres in the ECM appear quasi-one-dimensional (1D); similarly, a human hair does not appear to have significant width and hence is quasi-1D to the eye. Focal adhesions formed on 2D substrates are typically 1-10  $\mu\text{m}$  in size, much larger than the fibre diameter of the ECM<sup>21-23</sup>. This finite size effect limits the size of focal adhesions and the associated clusters of integrins and focal adhesion proteins that can be formed in cells embedded in a 3D matrix. Hence, although when in 2D culture a cell is in contact with a contiguous substrate, a cell in a 3D matrix has confined local contact with quasi-1D fibres.

Nevertheless, collagen fibres in a 3D matrix could support the formation of small and highly dynamic integrin clusters, with sizes on the order of tens of nanometres and lifetimes shorter than a few seconds, which may still be crucial to 3D cell motility. Moreover, cells *in vivo* could promote the bundling of collagen fibres through the generation of contractile forces produced by cellular protrusions. Such collagen bundles would enhance the surface area available and potentially promote the formation of larger adhesions<sup>24</sup>.

Actomyosin stress fibres, containing bundled actin filaments, have an important role in 2D cell motility as they provide the contractile forces required for the regulated detachment of the rear of a cell from the substratum and establish actin flow at the leading edge of the cell<sup>23,25</sup>. By contrast, cells display few stress fibres inside a 3D matrix and these are either localized to the cell cortex or radiate from the nucleus towards the plasma membrane to form pseudopodial protrusions<sup>26</sup>. Inhibition of actomyosin contractility is often substantially less effective in blocking 3D cell motility than in blocking 2D cell motility<sup>26</sup>, suggesting that the role of stress fibres is dependent on dimensionality<sup>25,27</sup>. Hence, eliminating the apical polarization of cells in 2D culture reduces the number of focal adhesions and stress fibres, and therefore fundamentally changes the role of components such as focal adhesion proteins and proteins highly enriched in stress fibres, such as the F-actin binding proteins  $\alpha$ -actinin, myosin II and tropomyosins.

In addition to having fewer focal adhesions and stress fibres when in a 3D matrix, cancer cells and epithelial or endothelial cells inside a 3D matrix typically do not form the characteristic wide lamellipodium and associated filopodial protrusions at the periphery. Instead, they display a limited number of pseudopodial protrusions, typically of 10-20  $\mu\text{m}$  thickness, which is intermediate between a lamellipodium and filopodia<sup>16</sup>. Traction microscopy suggests that in 2D culture, a lamellipodium actively pulls the rest of the cell through nascent focal adhesions positioned at the edge of the lamellipodium<sup>28</sup>. By contrast, 3D traction microscopy reveals that cells inside a 3D matrix never push the surrounding matrix and only pull on surrounding fibres<sup>26,29</sup>. Substantial matrix traction only occurs in the vicinity of productive pseudopodial protrusions, which typically number between only one and five per cell at any time<sup>26</sup>. Interestingly, in a 3D matrix, pseudopodial protrusions pull with approximately equal forces at the leading and trailing cell edges. However, the timing of release of the pseudopodia from the collagen fibres is asymmetric, often creating a defect in the matrix in the wake of the cell. These results suggest a model for 3D cancer cell motility in which pseudopodial protrusions at the trailing edge of the cell release first, pulling the rear of the cell forwards. The partial digestion of the ECM in the wake of the cell results in biased motion, analogous to a biased ratchet. This defect does not allow the cell to retrace the tunnel formed during migration and, therefore, promotes highly persistent migration in a 3D matrix, compared to less persistent migration of the same cell on a 2D substrate<sup>20</sup>.

Pseudopodia also have a probing role in 3D matrices but are of no functional importance on 2D substrates, where the extracellular environment is compositionally and topologically uniform. The interplay between the growth of pseudopodia along the quasi-1D tracks provided by the collagen fibres, the magnitude of traction and local digestion mediated by MMPs has not been determined but is likely to be fundamentally different from the 2D case given the different shapes of membrane protrusions and the crucial importance of MMPs in 3D cell motility. As cellular traction on collagen fibres may activate MMPs<sup>30</sup>, the interplay among pulling by cell protrusions, MMP activity and net cell migration is likely to occur within a feedback loop.

Pseudopodial protrusion activity in 3D matrices is readily modulated by focal adhesion components. For example, the scaffolding protein p130CAS mediates a high number and

high growth rate of protrusions, whereas the mechanosensing protein zyxin represses protrusion activity and diminishes the rate of protrusion growth along collagen fibres. A recent study<sup>16</sup> showed that the number of protrusions per unit time as well as the growth rate of protrusions, as modulated by focal adhesion proteins, correlated strongly with tumour cell motility in 3D matrices, a correlation shared by sarcoma and carcinoma cells. For instance, the migration speed of p130CAS- and zyxin-depleted cells correlated with the number of protrusions generated per unit time by these cells in 3D matrices<sup>16</sup>. However, whereas p130CAS-depleted cells moved more slowly (and zyxin-depleted cells more rapidly) than control cells in 3D matrices, these depleted cells displayed the opposite motility phenotypes on flat substrates. Importantly, modulation of 3D cell motility by the depletion of specific focal adhesion proteins does not correlate with changes in motility on 2D substrates. For example, vinculin-depleted cells move at a similar speed to control cells on flat substrates, whereas they move faster than control cells inside a 3D matrix<sup>16</sup>. Therefore, the role of focal adhesion proteins in 2D cell motility is not predictive of their role in motility in more physiologically relevant 3D matrices. Such results suggest that high-throughput pharmacological screens for drugs that limit motility on 2D substrates could be misleading. Moreover, although the rate of filopodial protrusion does not seem to correlate with 2D cell speed, the rate of pseudopodial protrusion correlates with 3D cell speed<sup>16</sup>. This suggests that protrusion dynamics is not required per se for effective 2D motility, but may be crucial in establishing 3D motility.

Many features observed *in vivo* by intravital microscopy<sup>31</sup> have been recapitulated in 3D matrix constructs, including the highly persistent migration of single cells away from tumours, the role of actomyosin contractility in collective migration to lymphatic vessels and the crucial role of MMPs in cancer cell dispersion from a primary tumour site. Nevertheless much more needs to be done to validate 3D models for *in vitro* cancer studies.

Intravital imaging of mammary tumours in mice suggests that only a small number of cells leave the primary tumour sites, and that they undergo highly directed migration away from the tumour by travelling along collagen fibres<sup>1,32</sup>. Intravital microscopy of GFP-labelled breast cancer cells in mice suggests that these cells migrate as single cells towards blood capillaries, and as multicellular clusters preferentially towards lymphatic vessels<sup>33</sup>. Such collective migration requires the suppression of actomyosin contractility at intercellular adhesions, which is mediated by discoidin domain receptor family, member 1 (DDR1) and the polarity regulators PAR3 and PAR6 (REF. 34). To establish the *in vivo* relevance of *in vitro* 3D matrix-based models, it will be important to confirm the role of focal adhesion proteins in cancer cell motility (suggested by the *in vitro* 3D assays described above) using intravital microscopy.

## Signalling and motility in cancer cells

The role of other prominent proteins that normally localize to the lamellipodium and filopodia of cells in 3D matrices is largely unknown. These proteins include those that constitute the F-actin nucleating ARP2/3 complex and its activators neural Wiskott-Aldrich syndrome protein (NWASP), Wiskott-Aldrich syndrome protein family, member 1 (WASF1; also known as WAVE1), WASF2 and WASF3 (also known as SCAR3), the expression of which correlates with poor clinical outcomes in several types of cancer<sup>35,36</sup>. Expression of the F-actin bundling protein fascin, which localizes to filopodia in 2D cell cultures, also correlates with poor clinical outcomes in patients with breast cancer<sup>37</sup>. In addition, the tumour suppressor protein PTEN<sup>38</sup> has been shown to localize at the trailing edge of migrating cells<sup>39</sup>. Therefore, the development of therapeutic approaches targeting mediators of cell motility and invasion will require a greater understanding of the role of these proteins in the more physiological environment of a 3D matrix or *in vivo*.

MMP inhibition or depletion in carcinoma and fibrosarcoma cells has been observed to switch the mode of migration from a predominantly integrin-based motility to a faster amoeboid migration mode<sup>40</sup>. By contrast, inhibition of the master mediators of actomyosin contractility, ROCK and RHO, forces the adoption of a mesenchymal migration mode in cells with an intrinsic amoeboid shape when embedded in Matrigel<sup>41</sup>. These observations provide a possible explanation for the failed clinical trials of MMP inhibitors. However, these *in vitro* studies made use of pepsin-extracted collagen I and commercially available Matrigel, which are both largely uncrosslinked. In particular, pepsin extraction of collagen I results in larger pores during gelation<sup>15</sup> that are permissive for amoeboid migration. The motility of cancer cells in crosslinked collagen gels crucially requires MMPs, primarily MMP14 (also known as MT1-MMP)<sup>8,15,42</sup>. These seemingly contradictory results can be reconciled if MMP function depends on the collagen matrix microstructure, including the collagen concentration and crosslinking density. MMP inhibition would be effective in reducing cancer cell motility in highly crosslinked and/or concentrated regions of the matrix, but would be ineffective for poorly crosslinked and/or low density regions. Interestingly, recent results suggest that mechanical load can dramatically increase the rate of collagen proteolysis by MMP14 (REF. 43). Moreover, combined inhibition of MMPs and actomyosin contractility reduces cell migration more effectively than separate inhibition of MMPs or contractility<sup>26</sup>. These results suggest an important functional interplay between cellular contractility and local MMP-mediated collagen digestion that drives cell migration in 3D matrices.

There is accumulating evidence that the physical properties of the stroma have a crucial role in tumour initiation, progression and metastasis through interplay between physical forces and biochemical signals. For example, the stiffness of the stromal matrix and degree of orientation of matrix fibres near primary tumour sites strongly correlate with worse clinical outcomes. Both *in vitro* and *in vivo*, these two microstructural parameters alone greatly enhance cell proliferation and motility<sup>9,18,44-46</sup>.

## The role of cell mechanics in intravasation

During entry into, and exit from, the vascular system, tumour cells undergo dramatic shape changes, driven by cytoskeletal remodelling, that enable them to penetrate endothelial cell-cell junctions. The cytoplasm is a complex composite system that behaves like an elastic material (such as rubber) at high deformation rates but more like a viscous material (such as ketchup) that exhibits a yield stress at low deformation rates<sup>47</sup>. Elasticity reflects the ability of the cytoplasm to rebound following the application of a force, whereas viscosity measures the ability of the cytoplasm to undergo flow under external shear. However, as MMP-mediated digestion of the matrix seems to be only partial, the rate-limiting step in the migration of cancer cells within a matrix or across an endothelium may be the deformation of the interphase nucleus, which is the largest organelle in the cell<sup>48</sup> and is approximately ten times stiffer than the cytoplasm<sup>49,50</sup>. The elasticity of the nucleus seems to be determined by the nuclear lamina underlying the nuclear envelope<sup>49</sup> and by both chromatin organization<sup>51</sup> and linkers of the nucleus and cytoskeleton (LINC) complexes<sup>52-55</sup>. LINC complexes are protein assemblies that span the nuclear envelope and mediate physical connections between the nuclear lamina and the cytoskeleton<sup>52</sup>. These connections are mediated by interactions between SUN domain-containing proteins (including SUN1 and SUN2) and Klarsicht homology (KASH) domain-containing proteins at the outer nuclear membrane (including the nesprin 2 giant isoform and nesprin 3, which can bind actin directly or indirectly)<sup>56-58</sup>. Indeed, depletion of LINC complex components, including nesprins and SUN proteins, leads to nuclear shape defects and an associated softening of the nucleus and the cytoplasm<sup>59</sup>. The nuclear lamina and LINC complex molecules have crucial roles in collective 2D migration<sup>54,55</sup>; however, their role in 3D motility remains to be



explored. Mutations that occur in nesprins and lamin A/C that have been found in breast cancer<sup>40</sup> could cause changes in LINC-mediated connections between the nucleus and cytoskeleton and, in turn, affect cancer cell 3D motility and invasiveness.

Biophysical measurements that compare the mechanical properties of normal and cancer cells have consistently shown that cancer cells are softer than normal cells and that this cellular compliance correlates with an increased metastatic potential<sup>60,61</sup>. In cancer cells, a softer cytoplasm correlates with a less-organized cytoskeleton. However, softening of the cytoskeleton has yet to be verified *in vivo* or in a 3D matrix in the presence and absence of interstitial flow. This is important as the physical properties of the environment, such as ECM stiffness<sup>62</sup> and dimensionality<sup>63-65</sup> and the presence of interstitial flow, regulate cell mechanics<sup>66</sup>. The development of new methods, such as particle-tracking microrheology<sup>47</sup>, will allow these measurements to be carried out in animal models, enabling a direct test of the hypothesis that cancer cells display lower stiffness than non-transformed cells. Such a finding could be used as a biophysical diagnostic marker of disease and metastatic potential<sup>60</sup>. We note that the reason why cancer cells may be softer than non-transformed cells is not currently known.

Migration through a 3D matrix and penetration through an endothelium is likely to require optimal mechanical properties: if they are too stiff or too soft, cells cannot deform the highly crosslinked collagen fibres of the matrix to migrate efficiently. However, single-cell measurements have consistently revealed that individual cells of a particular cell type are usually heterogeneous and display a wide range of mechanical properties. This suggests that cells with the optimal mechanical properties for invasion and intravasation into blood vessels are likely to preserve this phenotype over several generations. If mechanical properties are determined randomly on cell division, the broad distribution of mechanical properties implies that migration and intravasation would be unlikely events. Therefore, an important question is whether the physical attributes of cancer cells, such as stiffness, are passed on from generation to generation. If these physical properties are inherited, then it may be possible to alter them, either through pharmacological inhibition or activation of proteins affecting cell mechanics, so that they are not optimal for stromal invasion and intravasation.

Different optimal mechanical properties are probably required for each step of the metastatic cascade. For example, the optimal mechanical properties for invasion into the stromal matrix near the primary tumour site could be different from the mechanical properties of cells that have optimal (efficient) intravasation. Hence the mechanical properties of cancer cells might dynamically change during the metastatic process to successfully survive the harsh and changing environment of blood vessels, lymphatic vessels and the stromal space. These differences in mechanical properties might also be modulated by biochemical gradients<sup>50</sup>, interstitial flows<sup>67</sup> and endogenous electric fields<sup>68</sup>.

## Shear stress and the circulatory system

During their transit through the circulatory system, tumour cells are subjected to haemodynamic forces, immunological stress and collisions with host cells, such as blood cells and the endothelial cells lining the vessel wall. All of these stresses could affect cell survival and the ability to establish metastatic foci. Only circulating tumour cells (CTCs) that overcome or even exploit the effects of fluid shear (see below) and immunosurveillance will adhere to the vascular endothelium of distant organs, exit the circulation and successfully enter these tissues. A tiny fraction of CTCs survive to generate metastases; most CTCs die or remain dormant<sup>69</sup>.

On entering the circulatory system, the trajectory or path of a tumour cell is influenced by a number of physical and mechanical parameters: the pattern of blood flow, the diameter of the blood vessels and the complex interplay between shear flow and intercellular adhesion that leads to the arrest of cell movement in larger vessels. Shear stress ( $\tau$ ) arises between adjacent layers of fluid (in this case blood) of viscosity ( $\mu$ ) moving at different velocities. The velocity of a fluid in a cylindrical tube is maximum at the centre and zero at the cylinder walls, and the relative velocities of parallel adjacent layers of fluid in laminar flow define the shear rate ( $d\gamma/dt \equiv \dot{\gamma}$ ) where  $\gamma$  is the amplitude of deformation and  $t$  is the time elapsed. Shear stress is defined by the product of fluid viscosity and shear rate, and has units of force per unit area (Newtons per square metre ( $\text{N m}^{-2}$ ) or dynes per square centimetre ( $\text{dyn cm}^{-2}$ )).

The viscosity of blood is about 4 centipoise (cP), which is considerably greater than the viscosity of water (0.7 cP at 37 °C), primarily owing to the presence of red blood cells. At shear rates greater than  $100 \text{ s}^{-1}$ , blood is considered a Newtonian fluid, implying that the shear stress increases linearly with shear rate. The normal time-averaged levels of shear stress vary between  $1\text{--}4 \text{ dyn cm}^{-2}$  in the venous circulation and  $4\text{--}30 \text{ dyn cm}^{-2}$  in the arterial circulation<sup>70</sup>. The maximum shear stress is experienced at the vessel wall. The mean blood velocity ( $v_{\text{av}}$ ) in arteries for a vessel of diameter  $d = 4 \text{ mm}$  is  $0.45 \text{ m s}^{-1}$ , whereas  $v_{\text{av}} = 0.1 \text{ m s}^{-1}$  in a  $5 \text{ mm}$  vein. The corresponding shear rates ( $d\gamma/dt = 8v_{\text{av}}/d$ ) are  $900 \text{ s}^{-1}$  in arteries and  $160 \text{ s}^{-1}$  in veins.

The interstitial fluid velocity in other tissues, such as cartilage and bone subjected to mechanical loading during daily activity, induces varying levels of fluid shear stress up to  $30 \text{ dyn cm}^{-2}$  (REFS 2,71). Cells in the gastrointestinal tract are also constantly subjected to peristalsis and fluid shear stresses up to  $30 \text{ dyn cm}^{-2}$ . Renal epithelial cells normally sense stresses up to  $0.5 \text{ dyn cm}^{-2}$  (REF. 72), which are significantly increased under pathological conditions such as hypertension.

Shear flow influences the translational and rotational motion of CTCs (see the next section) and hence determines the orientation and time constant associated with receptor–ligand interactions that lead to adhesion. Shear flow may also induce deformation of CTCs and margination towards the vessel walls. However, the magnitude of these effects and their influence on occlusion and adhesion remain to be determined. Surprisingly, little is known about the effects of shear flow on the viability and proliferation of CTCs.

## Extravasation of circulating tumour cells

For a circulating tumour cell to exit the circulatory system, it must first bind to a blood vessel wall. There are two mechanisms of arrest, physical occlusion and cell adhesion; the relative prevalence of these mechanisms depends on the local blood vessel diameter (FIG. 3).

### Physical occlusion

If a circulating tumour cell enters a vessel whose diameter is less than the circulating tumour cell ( $d_{\text{vessel}} < d_{\text{cell}}$ ), then arrest can occur by mechanical trapping (physical occlusion). As circulating tumour cells of epithelial origin are typically  $>10 \text{ }\mu\text{m}$  in size, physical occlusion occurs in small vessels or capillaries of  $<10 \text{ }\mu\text{m}$ . Arrest at branches in blood vessels in the brain, with subsequent extravasation and metastasis formation, has been observed by intravital microscopy in a mouse model<sup>73</sup>.

## Adhesion

Extravasation of a tumour cell from a large blood vessel ( $d_{\text{cell}} < d_{\text{vessel}}$ ) requires the adhesion of the cell to the vessel wall through the formation of specific bonds. The probability ( $P$ ) of arrest at a large vessel can be written as  $P \propto ft$ , where  $f$  is the collision frequency between membrane-bound receptors and endothelial ligands and  $t$  is the residence time<sup>74</sup>. The residence time is dependent on the shear force exerted on the cell and the adhesive forces associated with ligand-receptor pairs between the circulating tumour cell and the endothelial cells of the blood vessel wall. Increasing fluid shear is expected to increase the collision frequency with the endothelium but decrease the residence time of receptor-ligand pairs.

A cell moving along a vessel wall has both translational and tangential (angular) velocity (BOX 2). The translational velocity of a cell is always larger than the surface tangential velocity, resulting in a slipping motion relative to the stationary blood vessel wall. This slipping motion increases the encounter rate between a single receptor on a CTC and ligands on the vessel wall<sup>75</sup>. For a cell undergoing rotational motion, the rotation brings successive receptors on the CTC surface into contact with ligands on the vessel wall. The total adhesion strength depends in non-trivial ways on the tensile strength of the individual receptor–ligand bond and the number of the involved receptor–ligand pairs. For example, cell adhesion or cell aggregation assays have been used to quantify global cell-cell adhesion<sup>76,77</sup>. However, these assays linearly extrapolate multiple-bond avidity to evaluate receptor–ligand affinity, an oversimplification that neglects possible cooperative effects. The development of sophisticated biophysical tools for measuring the kinetic and micromechanical properties of single ligand-receptor bonds have allowed single-molecule affinity to be distinguished from multi-molecular avidity<sup>78,79</sup>.

The probability of arrest, leading to extravasation, is expected to be maximum at intermediate values of shear stress. The kinetic (ON and OFF rates) and micromechanical (tensile strength) properties of a single receptor-ligand bond dictate whether a bond will form at a prescribed shear stress level as well as the macroscopic pattern of cell adhesion (FIG. 4). For instance, the initiation of receptor-mediated cell adhesion under shear stress requires: a relatively fast ON rate, which allows receptor-ligand binding at relatively short interaction (encounter) timescales; sufficient tensile strength to resist the dispersive hydrodynamic force; and a relatively slow OFF rate, which will provide adequate bond lifetime, thereby facilitating the formation of additional bonds. Receptor-ligand pairs — such as the selectins and their ligands discussed below — that exhibit high tensile strengths, fast ON rates and relatively fast OFF rates can initiate binding under shear stress and mediate transient rolling interactions. Molecules with slower ON rates, such as integrins, can engage only after selectin-mediated cell binding or, in the absence of selectin-dependent interactions, at a very low shear stress. Integrin clustering is responsible for the multi-bond, firm adhesion of cells onto surfaces<sup>80</sup>. Thus, integrins are involved in the dissemination of tumour cells, and may also control angiogenesis and metastatic growth<sup>81</sup>.

## The nature of receptor-ligand interactions in the adhesion of CTCs

Evidence suggests that CTCs may escape immune surveillance and promote their egress from the circulatory system by associating with platelets. Direct evidence for the role of platelets in metastasis comes from studies in a mouse model showing the inhibition of metastasis by either pharmacological<sup>82</sup> or genetic<sup>83</sup> depletion of platelets, and the restoration of metastatic potential by platelet infusion<sup>84</sup>. It is thought that by forming heterotypic adhesive clusters with CTCs, platelets mask and protect CTCs from immune-mediated mechanisms of clearance<sup>85,86</sup>. Platelets may also facilitate tumour cell adhesion to the vessel wall<sup>87-89</sup> (FIG. 4) and release an array of bioactive compounds such as vascular endothelial



growth factor (VEGF) at points of attachment to the endothelium, thereby promoting vascular hyperpermeability and extravasation<sup>90</sup>. After tumour cells have exited the circulation, factors secreted from activated platelets can induce angiogenesis and stimulate growth at the metastatic site<sup>91</sup>. CTCs may also hijack polymorpho-nuclear leukocytes (PMNs) for arrest in the endothelium of distant organs. Microscopy studies have shown PMNs in close association with metastatic tumour cells during tumour cell arrest and extravasation *in vivo*<sup>92</sup>.

CTCs may also mimic the behaviour of neutrophils by directly binding to the vascular endothelium through selectin-mediated tethering and by cell rolling followed by strong adhesion<sup>87,93</sup>. Indeed, P-, L- and E-selectins facilitate cancer metastasis and tumour cell arrest in the microvasculature by mediating specific interactions between selectin-expressing host cells and ligands on tumour cells. The most direct evidence for the involvement of P-selectin (which is present on activated platelets and the endothelium) in the metastatic process is the marked inhibition of metastasis in P-selectin-knockout mice compared to wild-type controls in a colon carcinoma xenograft model<sup>94,95</sup>. Similarly, mice deficient in L-selectin, which is expressed only by leukocytes, have reduced levels of metastasis<sup>95</sup>. The extent of metastasis is further reduced in P- and L-selectin double-deficient mice<sup>95</sup>, thereby suggesting that P- and L-selectins have synergistic effects in the facilitation of metastatic spread. It is thought that tumour cells can form multicellular complexes with platelets and leukocytes (via P- and L-selectin-dependent mechanisms<sup>96,97</sup>, respectively). These multicellular complexes can then arrest in the microvasculature of distant organs, and can eventually extravasate and establish metastatic colonies. Interestingly, leukocyte L-selectin can also enhance metastasis by interacting with endothelial L-selectin ligands that are induced adjacent to established intravascular colon carcinoma cell emboli<sup>98</sup>. Endothelial E-selectin has also been shown to support metastatic spread *in vivo*<sup>99,100</sup>.

Selectins bind to sialofucosylated oligosaccharides, such as sialyl Lewis<sup>x</sup> (sLe<sup>x</sup>) and its isomer sLe<sup>a</sup>, which are present mainly on cell surface glycoproteins. Various metastatic tumour cells, such as colon and pancreatic carcinoma cells, express sialofucosylated glycoproteins such as CD44 variant isoforms, carcinoembryonic antigen (CEA) and podocalyxin (PODXL), all of which are recognized by selectins<sup>101-103</sup>. As overexpression of these moieties on tumour cells correlates with poor prognosis and tumour progression<sup>104</sup>, it appears that selectin-mediated adhesion to these sialofucosylated target molecules on tumour cells may represent an important determinant for metastatic spread. Thus, the intravascular phase of the metastatic process represents a key step in which therapeutic intervention may be successful<sup>105</sup>. We note that additional molecules, such as glycoprotein Iba (GPIba) and GPVI<sup>106,107</sup>, integrins and their counter receptors, intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1), may be involved in tumour cell-host cell interactions<sup>104</sup> (FIG. 4).

### The location of metastatic sites

The location of metastatic sites with respect to a primary tumour has been the subject of intense investigations for many years<sup>2,108-110</sup>. Analysis of autopsy data revealed that metastatic sites are not colonized randomly<sup>108,111</sup>. Although primary tumours are found to metastasize to many different sites, there is a higher probability of metastasis at certain sites. For example, prostate cancer tends to metastasize to bone marrow and the liver, whereas breast cancer tends to metastasize to bone marrow and the lungs. Pancreatic cancer and colon cancer tend to metastasize to the liver and the lungs.

The patterns of metastasis have been explained in terms of two hypotheses. The 'seed and soil' hypothesis states that a tumour cell will metastasize to a site where the local microenvironment is favourable<sup>112</sup>, just as a seed released by a plant will only grow if it

lands at a site where the soil is fertile. The ‘mechanical’ hypothesis states that metastasis is likely to occur at sites based on the pattern of blood flow<sup>108</sup>. Both blood flow (the mechanical hypothesis) and local microenvironment (the seed and soil hypothesis) are thought to have complementary roles in influencing the location of a metastatic site<sup>2,108</sup>.

Based on the preceding discussion of the arrest of circulating tumour cells, we can elaborate on the physics of the location of metastatic sites. Blood is circulated from most organs to the heart and then the lungs by the venous system, and is subsequently returned to the heart and circulated to the organs by the arterial system. The organ capillary beds are characterized by a network of small blood vessels. If a tumour cell encounters a capillary of diameter smaller than the size of the cell ( $d_{\text{cell}} > d_{\text{vessel}}$ ) then the probability of cell trapping by physical occlusion at that site is very high. For a metastasis to occur, the tumour cell must still extravasate and colonize the local tissue. In one study, more than 50% of metastases could be explained by the blood flow pattern between the primary and secondary site<sup>111</sup>. As cell trapping, extravasation and colonization occur in series, we can speculate that the probability of a metastasis occurring at a specific site in accordance with the mechanical hypothesis can be expressed as  $P \propto P_t \cdot P_{e,i} \cdot P_{c,i}$ , where  $P_t$  is the probability of encountering a vessel with diameter less than the cell diameter,  $P_{e,i}$  is the probability of extravasation at that site and  $P_{c,i}$  is the probability of colonization. The probability of extravasation and colonization is expected to be dependent on the local microenvironment.

Every collision between a circulating tumour cell and a blood vessel wall, where  $d_{\text{cell}} < d_{\text{vessel}}$ , has the potential to result in adhesion. If the residence time is sufficiently long, then the tumour cell may adhere to the blood vessel wall and then extravasate. The probability that the residence time is sufficiently long for eventual extravasation to occur is related to the local shear stress. A further complexity is that the expression levels for adhesion proteins are different in different organs and hence the strength of the receptor-ligand adhesion may also be organ-specific<sup>113</sup>. For the seed and soil hypothesis, we write the probability of metastasis occurring at a specific site  $i$  as  $P_i \propto P_{a,i} \cdot P_{e,i} \cdot P_{c,i}$ , where  $P_{a,i}$  is the probability that a collision at site  $i$  leads to adhesion and  $P_{e,i}$  and  $P_{c,i}$  are the same as defined above. From these considerations it is evident that the probability of metastasis occurring in a specific organ in both the mechanical hypothesis and the seed and soil hypothesis have common elements related to extravasation and colonization, both of which are dependent on the local microenvironment.

As described above, it is likely that there is an optimal range of shear stress, corresponding to values found in the venous system, to achieve a sufficiently long residence time. For example, *in vitro* adhesion assays reveal that metastatic tumour cells bind to the vascular endothelium under venous but not arterial levels of shear stress<sup>87,93,97</sup>. Furthermore, high shear stresses (12 dyn cm<sup>-2</sup>) similar to those encountered in the arterial circulation have been reported to result in cell cycle arrest of metastatic tumour cells, which facilitates their eradication by the immune system<sup>114</sup>. By contrast, evidence suggests that low levels of shear stress, typical of the venous system, may have opposite effects on intracellular signalling and tumour cell function. For example, venous shear stress has been suggested to induce an EMT, as shown by the shear-mediated internalization of E-cadherin in metastatic oesophageal OC-1 tumour cells<sup>115</sup>. Moreover, exposure of free-flowing OC-1 cells to a shear rate of 200 s<sup>-1</sup> increased their mobility and invasive capacity *in vitro*<sup>115</sup>. However, further studies are needed to establish whether these observations can be extended beyond the OC-1 tumour cell line, and whether fluid shear stress can increase the invasive potential of tumour cells *in vivo*.

## Conclusions

The physical interactions of cancer cells with the diverse microenvironments encountered during the metastatic process have a key role in the spread of cancer. Mechanical forces modulate cell motility in the architecturally complex extracellular matrix during invasion and in the vascular system during intra-vasation and extravasation. Shear flow in the vascular system dictates the trajectory of circulating tumour cells and has a role in regulating adhesion at blood vessel walls, a key step in extravasation. The emerging insight into the role of physical and mechanical processes in metastasis should contribute to the development of new approaches for cancer diagnosis and treatment. For instance, it is noteworthy that several drug candidates show potential when examined *in vitro* but fail in clinical trials. This failure may stem at least in part from the use of conventional *in vitro* systems that fail to replicate the physiological microenvironment in humans as well as the lack of cell-phenotypic measurements. Specifically, the effects of key microenvironmental physical properties on cancer and stromal cell responses to drug candidates have yet to be explored in a systematic fashion. These physical properties include mechanical forces, ECM stiffness and the ECM pore size and tortuosity. Moreover, current cutting-edge ‘-omic’ measurements conducted on patient specimens need to be complemented with state-of-the-art physical measurements of, for example, cell and tissue microrheology, cell and nuclear shape and cell-cell and cell-matrix adhesion (TABLE 1). Such a holistic approach could drastically reduce the divergent effects of potential drug candidates on cell responses in animal models and in patients, and could help us to identify the appropriate and efficacious targets for treatment.

## Acknowledgments

The authors gratefully acknowledge support from the US National Institutes of Health (grants U54CA143868, U54CA151838 and RO1CA101135).

## Glossary

<b>Amoeboid migration</b>	A mode of three-dimensional cell migration in a matrix that involves dynamic cell-shape changes through actomyosin assembly and contractility, and adhesion to the extracellular matrix.
<b>Epithelial-to-mesenchymal transition</b>	(EMT). A morphological change that epithelial cells undergo, from a cubical to an elongated shape, following oncogenic transformation, which is often accompanied by loss of expression of the adhesion molecule E-cadherin. Post-EMT, cells adopt a high-motility phenotype.
<b>Filopodia</b>	Narrow projections of the cytoplasm extended beyond the lamellipodia of migrating cells. Filopodia are associated with the formation of nascent focal adhesions with a substratum.
<b>Focal adhesions</b>	Integrin clusters located at the basal surface of adherent cells that connect the extracellular matrix to the cytoskeleton through focal adhesion proteins.
<b>Interstitial flow</b>	Fluid flow in the extracellular matrix, often associated with lymphatic drainage of plasma back to the vascular system.
<b>Intravital microscopy</b>	A microscopy technique used for the observation of biological responses, such as leukocyte-endothelial cell interactions, in living

	tissues in real time. Translucent tissues are commonly used, such as the mesentery or cremaster muscle, which can be easily exteriorized for microscopic observation.
<b>Lamellipodia</b>	Large cytoplasmic projects found primarily at the leading edge of migrating cells, particularly on two-dimensional substrates.
<b>Mechanosensing</b>	The ability of cells to sense and respond to changes in the mechanical compliance of a substrate. Mechanosensing is mediated by focal adhesions and the cytoskeleton in two-dimensional cell culture.
<b>Mesenchymal migration</b>	A mode of three-dimensional cell migration in a matrix that involves integrin-based adhesion. Mesenchymal migration occurs when the pore size of the matrix is much smaller than the cell nucleus.
<b>Pseudopodia</b>	Bulges of constantly changing shape observed in the plasma membrane of migrating cells during amoeboid migration on two-dimensional substrates and mesenchymal migration through three-dimensional matrices.
<b>Shear rate</b>	The relative velocities of adjacent layers of fluid under shear force in conditions of laminar flow.
<b>Shear stress</b>	The magnitude of the tangential force applied onto the surface of an object per unit area. Shear stress is expressed in units of force per unit area (Newtons m <sup>-2</sup> in metres kilograms seconds (MKS) units or dynes cm <sup>-2</sup> in centimetres grams seconds (CGS) units).
<b>Stiffness</b>	(Also known as elasticity or elastic modulus). A measure of the ability of a material to resist shear forces similarly to a solid. Rubber is elastic and shows little viscosity. A crosslinked collagen matrix is elastic, but not viscous as it does not flow. The cytoplasm of cells is both elastic and viscous (viscoelastic) depending on the rate of deformation.
<b>Stress fibres</b>	Contractile actin filament bundles that contain myosin II, which serves both as an F-actin bundling protein and as a force generator. Stress fibres terminate at focal adhesions at the basal surface of cells on substrates.
<b>Surface tangential velocity</b>	The velocity at the surface of a spinning object.
<b>Translational velocity</b>	The velocity of an object in space.
<b>Viscosity</b>	A measure of the ability of a material to flow like a liquid. Water, glycerol and honey are liquids of increasing viscosity; they are only viscous and show no elasticity.

## References

1. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. *Nature Rev. Cancer*. 2002; 2:563–572. [PubMed: 12154349]
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. *Nature Med*. 2006; 12:895–904. [PubMed: 16892035]

3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J. Clin. Invest.* 2009; 119:1420–1428. [PubMed: 19487818]
4. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. *Science.* 2011; 331:1559–1564. [PubMed: 21436443]
5. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. *Nature Rev. Mol. Cell Biol.* 2006; 7:131–142. [PubMed: 16493418]
6. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nature Rev. Cancer.* 2009; 9:265–273. [PubMed: 19262571]
7. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. *Genes Dev.* 2006; 20:2673–2686. [PubMed: 16983145]
8. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. *Cell.* 2003; 114:33–45. [PubMed: 12859896]
9. Levental KR, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell.* 2009; 139:891–906. [PubMed: 19931152]
10. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. *Int. J. Cancer.* 2008; 123:2229–2238. [PubMed: 18777559]
11. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. *Oncogene.* 2009; 28:4326–4343. [PubMed: 19826415]
12. Ridley AJ, et al. Cell migration: integrating signals from front to back. *Science.* 2003; 302:1704–1709. [PubMed: 14657486]
13. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. *Cell.* 2003; 112:453–465. [PubMed: 12600310]
14. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. *Cell.* 1996; 84:359–369. [PubMed: 8608589]
15. Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. *J. Cell Biol.* 2009; 185:11–19. [PubMed: 19332889]
16. Fraley SI, et al. A distinctive role for focal adhesion proteins in three-dimensional cell motility. *Nature Cell Biol.* 2010; 12:598–604. [PubMed: 20473295]
17. Zaman MH, et al. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. *Proc. Natl Acad. Sci. USA.* 2006; 103:10889–10894. [PubMed: 16832052]
18. Wozniak MA, Desai R, Solski PA, Der CJ, Keely PJ. ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. *J. Cell Biol.* 2003; 163:583–595. [PubMed: 14610060]
19. Yamazaki D, Kurisu S, Takenawa T. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. *Oncogene.* 2009; 28:1570–1583. [PubMed: 19234490]
20. Doyle AD, Wang FW, Matsumoto K, Yamada KM. One-dimensional topography underlies three-dimensional fibrillar cell migration. *J. Cell Biol.* 2009; 184:481–490. [PubMed: 19221195]
21. Geiger B, Spatz JP, Bershadsky AD. Environmental sensing through focal adhesions. *Nature Rev. Mol. Cell Biol.* 2009; 10:21–33. [PubMed: 19197329]
22. Wehrle-Haller B, Imhof B. The inner lives of focal adhesions. *Trends Cell Biol.* 2002; 12:382–389. [PubMed: 12191915]
23. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. *Nature Rev. Mol. Cell Biol.* 2010; 11:633–643. [PubMed: 20729930]
24. Smith ML, et al. Force-induced unfolding of fibronectin in the extracellular matrix of living cells. *PLoS Biol.* 2007; 5:e268. [PubMed: 17914904]
25. Sun SX, Walcott S, Wolgemuth CW. Cytoskeletal cross-linking and bundling in motor-independent contraction. *Curr. Biol.* 2010; 20:R649–R654. [PubMed: 20692617]



26. Bloom RJ, George JP, Celedon A, Sun SX, Wirtz D. Mapping local matrix remodeling induced by a migrating tumor cell using three-dimensional multiple-particle tracking. *Biophys. J.* 2008; 95:4077–4088. [PubMed: 18641063]
27. Shih WT, Yamada S. Myosin IIA dependent retrograde flow drives 3D cell migration. *Biophys. J.* 2010; 98:L29–L31. [PubMed: 20409454]
28. Beningo KA, Dembo M, Kaverina I, Small JV, Wang YL. Nascent focal adhesions are responsible for the generation of strong propulsive forces in migrating fibroblasts. *J. Cell Biol.* 2001; 153:881–888. [PubMed: 11352946]
29. Legant WR, Miller JS, Blakely BL, Cohen DM, Genin GM, Chen CS. Measurement of mechanical tractions exerted by cells in three-dimensional matrices. *Nature Methods.* 2010; 7:969–971. [PubMed: 21076420]
30. Ellsmere JC, Khanna RA, Lee JM. Mechanical loading of bovine pericardium accelerates enzymatic degradation. *Biomaterials.* 1999; 20:1143–1150. [PubMed: 10382830]
31. Beerling E, Ritsma L, Vriesekoop N, Derksen PW, van Rheenen J. Intravital microscopy: new insights into metastasis of tumors. *J. Cell Sci.* 2011; 124:299–310. [PubMed: 21242309]
32. Sahai E, Wyckoff J, Philippar U, Segall JE, Gertler F, Condeelis J. Simultaneous imaging of, GFP, CFP and collagen in tumors in vivo using multiphoton microscopy. *BMC Biotechnol.* 2005; 5:14. [PubMed: 15910685]
33. Giampieri S, et al. Localized and reversible TGF- $\beta$  signalling switches breast cancer cells from cohesive to single cell motility. *Nature Cell Biol.* 2009; 11:1287–1296. [PubMed: 19838175]
34. Hidalgo-Carcedo C, et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. *Nature Cell Biol.* 2011; 13:49–58. [PubMed: 21170030]
35. Kurisu S, Takenawa T. WASP and WAVE family proteins: friends or foes in cancer invasion? *Cancer Sci.* 2010; 101:2093–2104. [PubMed: 20707804]
36. Iwaya K, Norio K, Mukai K. Coexpression of Arp2 and WAVE2 predicts poor outcome in invasive breast carcinoma. *Mod. Pathol.* 2007; 20:339–343. [PubMed: 17277766]
37. Yoder BJ, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. *Clin. Cancer Res.* 2005; 11:186–192. [PubMed: 15671545]
38. Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science.* 1997; 275:1943–1947. [PubMed: 9072974]
39. Iijima M, Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. *Cell.* 2002; 109:599–610. [PubMed: 12062103]
40. Wood LD, et al. The genomic landscapes of human breast and colorectal cancers. *Science.* 2007; 318:1108–1113. [PubMed: 17932254]
41. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. *Nature Cell Biol.* 2003; 5:711–719. [PubMed: 12844144]
42. Sounni NE, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. *FASEB J.* 2002; 16:555–564. [PubMed: 11919158]
43. Adhikari AS, Chai J, Dunn AR. Mechanical load induces a 100-fold increase in the rate of collagen proteolysis by MMP-1. *J. Am. Chem. Soc.* 2011; 133:1686–1689.
44. Kumar S, Weaver V. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. *Cancer Metastasis Rev.* 2009; 28:113–127. [PubMed: 19153673]
45. Paszek MJ, et al. Tensional homeostasis and the malignant phenotype. *Cancer Cell.* 2005; 8:241–254. [PubMed: 16169468]
46. Provenzano PP, Inman DR, Eliceiri KW, Trier SM, Keely PJ. Contact guidance mediated three-dimensional cell migration is regulated by Rho/ROCK-dependent matrix reorganization. *Biophys. J.* 2008; 95:5374–5384. [PubMed: 18775961]
47. Wirtz D. Particle-tracking microrheology of living cells: principles and applications. *Annu. Rev. Biophys.* 2009; 38:301–326. [PubMed: 19416071]

48. Friedl P, Wolf K, Lammerding J. Nuclear mechanics during cell migration. *Curr. Opin. Cell Biol.* 2010; 23:1–10. [PubMed: 21190823]
49. Dahl KN, Kahn SM, Wilson KL, Discher DE. The nuclear envelope lamina network has elasticity and a compressibility limit suggestive of a molecular shock absorber. *J. Cell Sci.* 2004; 117:4779–4786. [PubMed: 15331638]
50. Tseng Y, Lee JS, Kole TP, Jiang I, Wirtz D. Micro-organization and visco-elasticity of the interphase nucleus revealed by particle nanotracking. *J. Cell Sci.* 2004; 117:2159–2167. [PubMed: 15090601]
51. Gerlitz G, Bustin M. Efficient cell migration requires global chromatin condensation. *J. Cell Sci.* 2010; 123:2207–2217. [PubMed: 20530575]
52. Crisp M, et al. Coupling of the nucleus and cytoplasm: role of the LINC complex. *J. Cell Biol.* 2006; 172:41–53. [PubMed: 16380439]
53. Stewart-Hutchinson PJ, Hale CM, Wirtz D, Hodzic D. Structural requirements for the assembly of LINC complexes and their function in cellular mechanical stiffness. *Exp. Cell Res.* 2008; 314:1892–1905. [PubMed: 18396275]
54. Hale CM, et al. Dysfunctional connections between the nucleus and the actin and microtubule networks in laminopathic models. *Biophys. J.* 2008; 95:5462–5475. [PubMed: 18790843]
55. Lee JS, et al. Nuclear lamin A/C deficiency induces defects in cell mechanics, polarization, and migration. *Biophys. J.* 2007; 93:2542–2552. [PubMed: 17631533]
56. Starr DA, Han M. ANChors away: an actin based mechanism of nuclear positioning. *J. Cell Sci.* 2003; 116:211–216. [PubMed: 12482907]
57. Starr DA, et al. unc-83 encodes a novel component of the nuclear envelope and is essential for proper nuclear migration. *Development.* 2001; 128:5039–5050. [PubMed: 11748140]
58. Technau M, Roth S. The Drosophila KASH domain proteins Msp-300 and Klarsicht and the SUN domain protein klaroid have no essential function during oogenesis. *Fly (Austin).* 2008; 2:82–91. [PubMed: 18820478]
59. Lammerding J, et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. *J. Clin. Invest.* 2004; 113:370–378. [PubMed: 14755334]
60. Cross SE, Jin YS, Rao J, Gimzewski JK. Nanomechanical analysis of cells from cancer patients. *Nature Nanotech.* 2007; 2:780–783.
61. Guck J, et al. Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence. *Biophys. J.* 2005; 88:3689–3698. [PubMed: 15722433]
62. Yeung T, et al. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. *Cell Motil. Cytoskeleton.* 2005; 60:24–34. [PubMed: 15573414]
63. Panorchan P, Lee JS, Kole TP, Tseng Y, Wirtz D. Microrheology and ROCK signaling of human endothelial cells embedded in a 3D matrix. *Biophys. J.* 2006; 91:3499–3507. [PubMed: 16891369]
64. Baker EL, Bonnecaze RT, Zaman MH. Extracellular matrix stiffness and architecture govern intracellular rheology in cancer. *Biophys. J.* 2009; 97:1013–1021. [PubMed: 19686648]
65. Baker EL, Lu J, Yu DH, Bonnecaze RT, Zaman MH. Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential. *Biophys. J.* 2010; 99:2048–2057. [PubMed: 20923638]
66. Lee JS, et al. Ballistic intracellular nanorheology reveals ROCK-hard cytoplasmic stiffening response to fluid flow. *J. Cell Sci.* 2006; 119:1760–1768. [PubMed: 16636071]
67. Swartz MA, Fleury ME. Interstitial flow and its effects in soft tissues. *Annu. Rev. Biomed. Eng.* 2007; 9:229–256. [PubMed: 17459001]
68. Mycielska ME, Djamgoz MBA. Cellular mechanisms of direct-current electric field effects: galvanotaxis and metastatic disease. *J. Cell Sci.* 2004; 117:1631–1639. [PubMed: 15075225]
69. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. *Lancet Oncol.* 2002; 3:53–57. [PubMed: 11905606]
70. Turitto VT. Blood viscosity, mass transport, and thrombogenesis. *Prog. Hemost. Thromb.* 1982; 6:139–177. [PubMed: 6762611]
71. Weinbaum S, Cowin SC, Zeng Y. A model for the excitation of osteocytes by mechanical loading-induced bone fluid shear stresses. *J. Biomech.* 1994; 27:339–360. [PubMed: 8051194]

72. Weinbaum S, Duan Y, Satlin LM, Wang T, Weinstein AM. Mechanotransduction in the renal tubule. *Am. J. Physiol. Renal Physiol.* 2010; 299:F1220–F1236. [PubMed: 20810611]
73. Kienast Y, et al. Real-time imaging reveals the single steps of brain metastasis formation. *Nature Med.* 2010; 16:116–122. [PubMed: 20023634]
74. Zhu C, Yago T, Lou JZ, Zarnitsyna VI, McEver RP. Mechanisms for flow-enhanced cell adhesion. *Ann. Biomed. Eng.* 2008; 36:604–621. [PubMed: 18299992]
75. Chang KC, Hammer DA. The forward rate of binding of surface-tethered reactants: effect of relative motion between two surfaces. *Biophys. J.* 1999; 76:1280–1292. [PubMed: 10049312]
76. Duguay D, Foty RA, Steinberg MS. Cadherin-mediated cell adhesion and tissue segregation: qualitative and quantitative determinants. *Dev. Biol.* 2003; 253:309–323. [PubMed: 12645933]
77. Niessen CM, Gumbiner BM. Cadherin-mediated cell sorting not determined by binding or adhesion specificity. *J. Cell Biol.* 2002; 156:389–399. [PubMed: 11790800]
78. Huang J, et al. The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. *Nature.* 2010; 464:932–936. [PubMed: 20357766]
79. Marshall BT, Long M, Piper JW, Yago T, McEver RP, Zhu C. Direct observation of catch bonds involving cell-adhesion molecules. *Nature.* 2003; 423:190–193. [PubMed: 12736689]
80. Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell.* 2002; 110:673–687. [PubMed: 12297042]
81. Lorgier M, Krueger JS, O’Neal M, Staflin K, Felding-Habermann B. Activation of tumor cell integrin  $\alpha_v\beta_3$  controls angiogenesis and metastatic growth in the brain. *Proc. Natl Acad. Sci. USA.* 2009; 106:10666–10671. [PubMed: 19541645]
82. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. *Proc. Natl Acad. Sci. USA.* 1968; 61:46–52. [PubMed: 5246932]
83. Camerer E, et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. *Blood.* 2004; 104:397–401. [PubMed: 15031212]
84. Karparkin S, Pearlstein E, Ambrogio C, Collier BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. *J. Clin. Invest.* 1988; 81:1012–1019. [PubMed: 3280598]
85. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. *Cancer Res.* 1999; 59:1295–1300. [PubMed: 10096562]
86. Palumbo JS, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood.* 2005; 105:178–185. [PubMed: 15367435]
87. Burdick MM, Konstantopoulos K. Platelet-induced enhancement of LS174T colon carcinoma and THP-1 monocytoid cell adhesion to vascular endothelium under flow. *Am. J. Physiol. Cell Physiol.* 2004; 287:C539–C547. [PubMed: 15084476]
88. Felding-Habermann B, Habermann R, Salvidar E, Ruggeri ZM. Role of  $\beta_3$  integrins in melanoma cell adhesion to activated platelets under flow. *J. Biol. Chem.* 1996; 271:5892–5900. [PubMed: 8621462]
89. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. *Nature Rev. Cancer.* 2011; 11:123–134. [PubMed: 21258396]
90. Nash G, Turner L, Scully M, Kakkar A. Platelets and cancer. *Lancet Oncol.* 2002; 3:425–430. [PubMed: 12142172]
91. Pinedo HM, Verheul HM, D’Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? *Lancet.* 1998; 352:1775–1777. [PubMed: 9848370]
92. Crissman JD, Hatfield J, Schaldenbrand M, Sloane BF, Honn KV. A light and electron microscopic study. Arrest and extravasation of B16 amelanotic melanoma in murine lungs. *Lab. Invest.* 1985; 53:470–478. [PubMed: 4046557]
93. Burdick MM, McCaffery JM, Kim YS, Bochner BS, Konstantopoulos K. Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate adhesion to HUVECs under flow. *Am. J. Physiol. Cell Physiol.* 2003; 284:C977–C987. [PubMed: 12477667]
94. Borsig L, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. *Proc. Natl Acad. Sci. USA.* 2001; 98:3352–3357. [PubMed: 11248082]

95. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. *Proc. Natl Acad. Sci. USA.* 2002; 99:2193–2198. [PubMed: 11854515]
96. Jadhav S, Bochner BS, Konstantopoulos K. Hydrodynamic shear regulates the kinetics and receptor specificity of polymorphonuclear leukocyte – colon carcinoma cell adhesive interactions. *J. Immunol.* 2001; 167:5986–5993. [PubMed: 11698478]
97. McCarty OJT, Mousa SA, Bray PF, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling and firm adhesion under dynamic flow conditions. *Blood.* 2000; 96:1789–1797. [PubMed: 10961878]
98. Laubli H, Stevenson JL, Varki A, Varki NM, Borsig L. L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. *Cancer Res.* 2006; 66:1536–1542. [PubMed: 16452210]
99. Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. Redirection of tumor metastasis by expression of E-selectin in vivo. *J. Exp. Med.* 1996; 183:581–587. [PubMed: 8627169]
100. Mannori G, et al. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. *Am. J. Pathol.* 1997; 151:233–243. [PubMed: 9212748]
101. Napier SL, Healy ZR, Schnaar RL, Konstantopoulos K. Selectin ligand expression regulates the initial vascular interactions of colon carcinoma cells: the roles of CD44v and alternative sialofucosylated selectin ligands. *J. Biol. Chem.* 2007; 282:3433–3441. [PubMed: 17135256]
102. Thomas SN, Schnaar RL, Konstantopoulos K. Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells. *Am. J. Physiol. Cell Physiol.* 2009; 296:C505–C513. [PubMed: 19118161]
103. Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K. Carcinoembryonic antigen and CD44v cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. *J. Biol. Chem.* 2008; 283:15647–15655. [PubMed: 18375392]
104. Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. *Annu. Rev. Biomed. Eng.* 2009; 11:177–202. [PubMed: 19413512]
105. Varki A, Varki NM, Borsig L. Molecular basis of metastasis. *N. Engl. J. Med.* 2009; 360:1678–1679. author reply 1679–1680. [PubMed: 19369678]
106. Jain S, et al. Platelet glycoprotein Iba supports experimental lung metastasis. *Proc. Natl Acad. Sci. USA.* 2007; 104:9024–9028. [PubMed: 17494758]
107. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. *J. Thromb. Haemost.* 2009; 7:1713–1717. [PubMed: 19624454]
108. Weiss L. Patterns of metastasis. *Cancer Metastasis Rev.* 2000; 19:281–301.
109. Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. *Expert Rev. Proteomics.* 2007; 4:741–756. [PubMed: 18067413]
110. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. *Nature Rev. Cancer.* 2003; 3:453–458. [PubMed: 12778135]
111. Weiss L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. *Clin. Exp. Metastasis.* 1992; 10:191–199. [PubMed: 1582089]
112. Paget S. The distribution of secondary growths in cancer of the breast. *Lancet.* 1889; 1:571–573.
113. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. *Curr. Opin. Chem. Biol.* 2002; 6:399–404. [PubMed: 12023122]
114. Chang SF, et al. Tumor cell cycle arrest induced by shear stress: roles of integrins and Smad. *Proc. Natl Acad. Sci. USA.* 2008; 105:3927–3932. [PubMed: 18310319]
115. Lawler K, O’Sullivan G, Long A, Kenny D. Shear stress induces internalization of E-cadherin and invasiveness in metastatic oesophageal cancer cells by a Src-dependent pathway. *Cancer Sci.* 2009; 100:1082–1087. [PubMed: 19432901]
116. Raub CB, et al. Noninvasive assessment of collagen gel microstructure and mechanics using multiphoton microscopy. *Biophys. J.* 2007; 92:2212–2222. [PubMed: 17172303]
117. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. *Nature Rev. Mol. Cell Biol.* 2006; 7:211–224. [PubMed: 16496023]

118. Buxboim A, Ivanovska IL, Discher DE. Matrix elasticity, cytoskeletal forces and physics of the nucleus: how deeply do cells 'feel' outside and in? *J. Cell Sci.* 2010; 123:297–308. [PubMed: 20130138]
119. Goldman AJ, Cox RG, Brenner H. Slow viscous motion of a sphere parallel to a plane wall — 2 Couette flow. *Chem. Eng. Sci.* 1967; 22:653–660.
120. Hanley WD, Wirtz D, Konstantopoulos K. Distinct kinetic and mechanical properties govern selectin-leukocyte interactions. *J. Cell Sci.* 2004; 117:2503–2511. [PubMed: 15159451]
121. Panorchan P, et al. Single-molecule analysis of cadherin-mediated cell-cell adhesion. *J. Cell Sci.* 2006; 119:66–74. [PubMed: 16371651]
122. Raman P, Alves C, Wirtz D, Konstantopoulos K. Single molecule binding of CD44 to fibrin versus P-selectin predicts their distinct shear-dependent interactions in cancer. *J. Cell Sci.* 2011; 124:1903–1910. [PubMed: 21558419]
123. Li F, Redick SD, Erickson HP, Moy VT. Force measurements of the  $\alpha 5 \beta 1$  integrin-fibronectin interaction. *Biophys. J.* 2003; 84:1252–1262. [PubMed: 12547805]
124. Bajpai S, et al.  $\alpha$ -Catenin mediates initial E-cadherin-dependent cell-cell recognition and subsequent bond strengthening. *Proc. Natl Acad. Sci. USA.* 2008; 105:18331–18336. [PubMed: 19017792]
125. Bajpai S, Feng Y, Krishnamurthy R, Longmore GD, Wirtz D. Loss of  $\alpha$ -catenin decreases the strength of single E-cadherin bonds between human cancer cells. *J. Biol. Chem.* 2009; 284:18252–18259. [PubMed: 19458087]
126. Garcia AJ, Ducheyne P, Boettiger D. Quantification of cell adhesion using a spinning disc device and application to surface-reactive materials. *Biomaterials.* 1997; 18:1091–1098. [PubMed: 9247346]
127. DeGrendele HC, Kosfisz M, Estess P, Siegelman MH. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. *J. Immunol.* 1997; 159:2549–2553. [PubMed: 9300670]
128. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. *Nature.* 1997; 385:537–540. [PubMed: 9020360]
129. Azioune A, Storch M, Bornens M, Thery M, Piel M. Simple and rapid process for single cell micro-patterning. *Lab. Chip.* 2009; 9:1640–1642. [PubMed: 19458875]
130. Thery M, Bornens M. Cell shape and cell division. *Curr. Opin. Cell Biol.* 2006; 18:648–657. [PubMed: 17046223]
131. Khatau SB, et al. A perinuclear actin cap regulates nuclear shape. *Proc. Natl Acad. Sci. USA.* 2009; 106:19017–19022. [PubMed: 19850871]
132. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Geometric control of cell life and death. *Science.* 1997; 276:1425–1428. [PubMed: 9162012]
133. Mali P, Wirtz D, Searson PC. Interplay of RhoA and motility in the programmed spreading of daughter cells postmitosis. *Biophys. J.* 2010; 99:3526–3534. [PubMed: 21112276]
134. Wildt B, Wirtz D, Searson PC. Programmed subcellular release for studying the dynamics of cell detachment. *Nature Methods.* 2009; 6:211–213. [PubMed: 19182793]
135. Wildt B, Wirtz D, Searson PC. Triggering cell detachment from patterned electrode arrays by programmed subcellular release. *Nature Protoc.* 2010; 5:1273–1280. [PubMed: 20595956]
136. Ghaly T, Wildt BE, Searson PC. Electrochemical release of fluorescently labeled thiols from patterned gold surfaces. *Langmuir.* 2010; 26:1420–1423. [PubMed: 19902935]
137. Sniadecki NJ, Lamb CM, Liu Y, Chen CS, Reich DH. Magnetic microposts for mechanical stimulation of biological cells: fabrication, characterization, and analysis. *Rev. Sci. Instrum.* 2008; 79:044302. [PubMed: 18447536]
138. Tan JL, et al. Cells lying on a bed of microneedles: an approach to isolate mechanical force. *Proc. Natl Acad. Sci. USA.* 2003; 100:1484–1489. [PubMed: 12552122]
139. Dembo M, Wang YL. Stresses at the cell-to-substrate interface during locomotion of fibroblasts. *Biophys. J.* 1999; 76:2307–2316. [PubMed: 10096925]



140. Song B, et al. Application of direct current electric fields to cells and tissues in vitro and modulation of wound electric field in vivo. *Nature Protoc.* 2007; 2:1479–1489. [PubMed: 17545984]
141. Huang CW, Cheng JY, Yen MH, Young TH. Electrotaxis of lung cancer cells in a multiple-electric-field chip. *Biosens. Bioelectron.* 2009; 24:3510–3516. [PubMed: 19497728]
142. Lee JS, Chang MI, Tseng Y, Wirtz D. Cdc42 mediates nucleus movement and MTOC polarization in Swiss 3T3 fibroblasts under mechanical shear stress. *Mol. Biol. Cell.* 2005; 16:871–880. [PubMed: 15548602]
143. Wojciak-Stothard B, Ridley AJ. Shear stress-induced endothelial cell polarization is mediated by Rho and Rac but not Cdc42 or PI 3-kinases. *J. Cell Biol.* 2003; 161:429–439. [PubMed: 12719476]
144. Gomes ER, Jani S, Gundersen GG. Nuclear movement regulated by Cdc42, MRCK, myosin, and actin flow establishes MTOC polarization in migrating cells. *Cell.* 2005; 121:451–463. [PubMed: 15882626]
145. Poujade M, et al. Collective migration of an epithelial monolayer in response to a model wound. *Proc. Natl Acad. Sci. USA.* 2007; 104:15988–15993. [PubMed: 17905871]
146. Daniels BR, Masi BC, Wirtz D. Probing single-cell micromechanics in vivo: the microrheology of *C. elegans* developing embryos. *Biophys. J.* 2006; 90:4712–4719. [PubMed: 16581841]
147. Massiera G, Van Citters KM, Biancaniello PL, Crocker JC. Mechanics of single cells: rheology, time dependence, and fluctuations. *Biophys. J.* 2007; 93:3703–3713. [PubMed: 17693461]
148. Solon J, Levental I, Sengupta K, Georges PC, Janmey PA. Fibroblast adaptation and stiffness matching to soft elastic substrates. *Biophys. J.* 2007; 93:4453–4461. [PubMed: 18045965]
149. Zhou X, et al. Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. *Genes Dev.* 2008; 22:1231–1243. [PubMed: 18451110]
150. Wang N, Butler JP, Ingber DE. Mechanotransduction across the cell surface and through the cytoskeleton. *Science.* 1993; 260:1124–1127. [PubMed: 7684161]
151. Rahman A, Tseng Y, Wirtz D. Micromechanical coupling between cell surface receptors and RGD peptides. *Biochem. Biophys. Res. Commun.* 2002; 296:771–778. [PubMed: 12176050]
152. Kishino A, Yanagida T. Force measurements by micromanipulation of a single actin filament by glass needles. *Nature.* 1988; 334:74–76. [PubMed: 3386748]
153. Zheng J, et al. Tensile regulation of axonal elongation and initiation. *J. Neurosci.* 1991; 11:1117–1125. [PubMed: 2010807]
154. Kumar S, et al. Viscoelastic retraction of single living stress fibers and its impact on cell shape, cytoskeletal organization, and extracellular matrix mechanics. *Biophys. J.* 2006; 90:3762–3773. [PubMed: 16500961]
155. Grill SW, Gonczy P, Stelzer EH, Hyman AA. Polarity controls forces governing asymmetric spindle positioning in the *Caenorhabditis elegans* embryo. *Nature.* 2001; 409:630–633. [PubMed: 11214323]
156. Grill SW, Howard J, Schaffer E, Stelzer EH, Hyman AA. The distribution of active force generators controls mitotic spindle position. *Science.* 2003; 301:518–521. [PubMed: 12881570]
157. Pajeroski JD, Dahl KN, Zhong FL, Sammak PJ, Discher DE. Physical plasticity of the nucleus in stem cell differentiation. *Proc. Natl Acad. Sci. USA.* 2007; 104:15619–15624. [PubMed: 17893336]
158. Hochmuth RM. Micropipette aspiration of living cells. *J. Biomech.* 2000; 33:15–22. [PubMed: 10609514]
159. Lo CM, Wang HB, Dembo M, Wang YL. Cell movement is guided by the rigidity of the substrate. *Biophys. J.* 2000; 79:144–152. [PubMed: 10866943]
160. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. *Cell.* 2006; 126:677–689. [PubMed: 16923388]
161. Gerecht S, et al. The effect of actin disrupting agents on contact guidance of human embryonic stem cells. *Biomaterials.* 2007; 28:4068–4077. [PubMed: 17576011]
162. Karuri NW, et al. Biological length scale topography enhances cell-substratum adhesion of human corneal epithelial cells. *J. Cell Sci.* 2004; 117:3153–3164. [PubMed: 15226393]


163. Teixeira AI, Abrams GA, Bertics PJ, Murphy CJ, Nealey PF. Epithelial contact guidance on well-defined micro- and nanostructured substrates. *J. Cell Sci.* 2003; 116:1881–1892. [PubMed: 12692189]
164. Kaspar D, Seidl W, Neidlinger-Wilke C, Ignatius A, Claes L. Dynamic cell stretching increases human osteoblast proliferation and CICP synthesis but decreases osteocalcin synthesis and alkaline phosphatase activity. *J. Biomech.* 2000; 33:45–51. [PubMed: 10609517]
165. Hubbell J. Biomaterials in tissue engineering. *Biotechnology.* 1995; 13:565–576. [PubMed: 9634795]
166. Irimia D, Toner M. Spontaneous migration of cancer cells under conditions of mechanical confinement. *Integr Biol. (Camb.).* 2009; 1:506–512. [PubMed: 20023765]
167. Wang CJ, Levchenko A. Microfluidics technology for systems biology research. *Methods Mol. Biol.* 2009; 500:203–219. [PubMed: 19399428]
168. Sundararaghavan HG, Monteiro GA, Firestein BL, Shreiber DI. Neurite growth in 3D collagen gels with gradients of mechanical properties. *Biotechnol. Bioeng.* 2009; 102:632–643. [PubMed: 18767187]
169. Quake SR, Scherer A. From micro- to nanofabrication with soft materials. *Science.* 2000; 290:1536–1540. [PubMed: 11090344]
170. Rogers SS, Waigh TA, Lu JR. Intracellular microrheology of motile *Amoeba proteus*. *Biophys. J.* 2008; 94:3313–3322. [PubMed: 18192370]
171. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. *Nature Rev. Cancer.* 2003; 3:921–930. [PubMed: 14737122]
172. Kedrin D, et al. Intravital imaging of metastatic behavior through a mammary imaging window. *Nature Methods.* 2008; 5:1019–1021. [PubMed: 18997781]
173. Phair RD, Misteli T. High mobility of proteins in the mammalian cell nucleus. *Nature.* 2000; 404:604–609. [PubMed: 10766243]
174. Phair RD, Misteli T. Kinetic modelling approaches to in vivo imaging. *Nature Rev. Mol. Cell Biol.* 2001; 2:898–907. [PubMed: 11733769]
175. Pertz O, Hahn KM. Designing biosensors for Rho family proteins — deciphering the dynamics of Rho family GTPase activation in living cells. *J. Cell Sci.* 2004; 117:1313–1318. [PubMed: 15020671]
176. Nalbant P, Hodgson L, Kraynov V, Touthkine A, Hahn KM. Activation of endogenous Cdc42 visualized in living cells. *Science.* 2004; 305:1615–1619. [PubMed: 15361624]
177. Moerner WE, Orrit M. Illuminating single molecules in condensed matter. *Science.* 1999; 283:1670–1676. [PubMed: 10073924]
178. Magde D, Elson EL, Webb WW. Fluorescence correlation spectroscopy. II. An experimental realization. *Biopolymers.* 1974; 13:29–61. [PubMed: 4818131]
179. Daniels BR, Perkins EM, Dobrowsky TM, Sun SX, Wirtz D. Asymmetric enrichment of PIE-1 in the *Caenorhabditis elegans* zygote mediated by binary counterdiffusion. *J. Cell Biol.* 2009; 184:473–479. [PubMed: 19221192]
180. Huang B, Bates M, Zhuang X. Super-resolution fluorescence microscopy. *Annu. Rev. Biochem.* 2009; 78:993–1016. [PubMed: 19489737]
181. Huang B, Wang W, Bates M, Zhuang X. Three-dimensional super-resolution imaging by stochastic optical reconstruction microscopy. *Science.* 2008; 319:810–813. [PubMed: 18174397]
182. Betzig E, et al. Imaging intracellular fluorescent proteins at nanometer resolution. *Science.* 2006; 313:1642–1645. [PubMed: 16902090]

**Box 1 | The extracellular matrix**

The extracellular matrix (ECM) is a complex composite material consisting of proteoglycan hydrogel coupled to an assembly of crosslinked collagen fibres that are typically 100 nm or less in diameter<sup>116</sup>. The unique three-dimensional architecture provides structural support and also allows sensing and transduction of biochemical and mechanical signals to cells<sup>117</sup>. The properties of the ECM are tissue-dependent: for example, the elasticity of ECM varies from less than 1 kPa in the brain to 100 kPa in skeletal tissues<sup>118</sup>. The interstitial space in the ECM is occupied by fluid that is usually in motion and provides a dynamic environment for cells<sup>67</sup>. The permeability of the ECM is dependent on its composition and structure. The development of *in vitro* models of ECM that can mimic tissue-specific physicochemical properties, molecular composition, elasticity, pore size and local fibre orientation will be crucial to further advance our understanding of cancer cell motility in three dimensions and how this relates to migration *in vivo*.

### Box 2 | Fluid shear stress and slipping velocity


For a moving spherical object with translational velocity ( $v_{\text{cell}}$ ), the angular velocity ( $\omega$ ) describes the rate of spinning about its rotational axis, and the surface tangential velocity ( $v_{\text{tg}}$ ) describes the velocity at the surface. For example, the translational velocity of the earth (about  $30 \text{ km s}^{-1}$ ) results in one rotation around the sun in one year. The angular velocity results in one rotation around the polar axis in one day (about  $2\pi$  radians per day) and is independent of longitude. The surface tangential velocity is highest at the equator and is about  $465 \text{ m s}^{-1}$ . For a spherical object in contact with a surface in a low viscosity fluid, such as air, the translational velocity is synchronized with the angular velocity. This situation can be envisioned as a ball rolling along the floor where  $v_{\text{tg}}/v_{\text{cell}} = 1$ . Numerical solutions of  $v_{\text{tg}}/v_{\text{cell}}$  (REF. 119) show that for a spherical cell touching the surface in a viscous fluid,  $v_{\text{tg}}/v_{\text{cell}} = 0.57$ . Therefore, both translational motion and rotation along a vessel wall contribute to receptor-ligand interactions. In the absence of a slipping motion, each cell receptor can only interact with a limited number of immobilized counter-receptors located within its reactive zone. Binding occurs only when the separation distance between a receptor and a ligand is sufficiently small, within the reactive radius around a receptor. Thus, when a free ligand is brought inside this reactive zone, the complex will react. By contrast, when a cell moves with a finite slipping velocity, each cell receptor can potentially bind to any counter receptor present within its reactive zone. Thus, the slipping velocity has been reported to enhance the receptor-ligand encounter rate<sup>75</sup>.



**Figure 1. The metastatic process**


In this complex process, cells detach from a primary, vascularized tumour, penetrate the surrounding tissue, enter nearby blood vessels (intravasation) and circulate in the vascular system. Some of these cells eventually adhere to blood vessel walls and are able to extravasate and migrate into the local tissue, where they can form a secondary tumour.






**Figure 2. The physics of invasion and intravasation**

The epithelial-to-mesenchymal transition (EMT) is associated with a loss of adhesion through downregulation of E-cadherin (E-cad) and a change in morphology. Invasion by tumour cells of the surrounding tissue and subsequent motion is dictated by the physicochemical properties of the extracellular matrix (ECM). By squeezing between blood vessel endothelial cells, tumour cells can enter the vascular system. All of these steps involve physicochemical processes, such as adhesion and deformation, that are dependent on the local environment. LOX, lysyl oxidase; MMPs, matrix metalloproteinases; N-cad, N-cadherin.



**Figure 3. Arrest of circulating tumour cells**

Tumour cells with a diameter ( $d_{\text{cell}}$ ) less than the diameter of the blood vessel wall ( $d_{\text{vessel}}$ ) will follow a trajectory that is determined by the local flow pattern and by collisions with host cells and blood vessel walls. Collisions with a blood vessel wall may lead to arrest. Tumour cells with diameter greater than the diameter of a blood vessel will be arrested owing to mechanical trapping (physical occlusion).



**Figure 4. Capture and arrest of circulating tumour cells**

**a** | A collision between a cell and a vessel wall may lead to transient and/or persistent (firm) adhesion as a result of ligand-receptor interactions. Transient adhesion is characterized by weaker bonds involving ligands such as CD44, carcinoembryonic antigen (CEA) or podocalyxin (PODXL) binding with selectin receptors. Persistent adhesion either follows transient binding or is initiated at very low shear stress and involves interactions between integrins and their receptors, such as intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1). For consistency we designate the adhesion molecules on the surface of endothelial cells as receptors and the interacting molecules on the circulating tumour cells as ligands. We note that in the literature, integrins participating in receptor-ligand pairs are usually identified as receptors. **b** | The association of tumour cells with platelets may enhance arrest through platelet-mediated capture, a process analogous to nucleation and growth. The growth process is achieved by a platelet-bridging mechanism, whereby platelets adherent to an endothelium-bound carcinoma cell serve as a ‘nucleus’ to capture free-flowing cells that subsequently attach to the blood vessel wall downstream or next to the already adherent cell. This nucleation mechanism, which is primarily dependent on P-selectin, results in the formation of growing clusters of adherent cells.

Table 1

Tools for the study of the physics of cancer

Tool or technique	Application	Refs
<b>Cellular adhesion and migration</b>		
Single-molecule force spectroscopy	Measurements of cell–matrix and cell–cell adhesion at single-molecule resolution; measurement of single ligand–receptor binding <i>in vivo</i>	120–125
Flow chamber assays	Measurement of global cell–matrix adhesion	103, 126–128
Adhesive micropatterns	Control of cell and nuclear shape and size; control of axis of cell division; high-throughput drug testing	129–133
Adhesive nanopatterns	Control of subcellular adhesion; integrin clustering	21
Programmed subcellular release	Controlled localized detachment of cells from substrates	134 – 136
Deformable pillars	Measurement of local traction forces generated by cells; application of localized forces to the basal surface of cells	137, 138
3D traction microscopy	Measurement of cell-induced 3D matrix remodelling	26
2D traction microscopy	Measurement of forces generated by cells on 2D substrates	139
Galvanotaxis	Measurement of the influence of electric field on motility	140, 141
<b>Controlled cellular polarization</b>		
Flow chambers	Measurements of cell polarization induced by flow and mechanotransduction	142, 143
Wound-healing	Measurements of migration and polarization during collective cell migration	144
Single-cell motility	Measurement of motility parameters for cells on substrates and in 3D matrices	16
Micropatterns for wound-healing	Measurement and control of cell polarization during collective cell migration	145 – 147
<b>Cellular and nuclear mechanics</b>		
Atomic force microscopy	Measurement of cellular and single-molecule mechanics; imaging of cells at the nanoscale; application of controlled forces to the apical surface of cells	45, 62, 148
Particle tracking microrheology	Measurement of intracellular, nuclear and extracellular matrix mechanics <i>in vitro</i> and <i>in vivo</i>	50, 63, 149
Magnetic/optical tweezers	Measurement of cellular and subcellular mechanics; application of localized forces at the cell surface and in the cytoplasm	61, 150
Calibrated microneedles	Application of localized forces to the apical surface of cells and measurement of cell mechanotransduction	151 – 153
Laser ablation	Ablation of cytoskeletal fibres	154 – 156
Micropipette suction	Measurement of cellular and nuclear mechanics	49, 157, 158
<b>Controlled microenvironment</b>		

Tool or technique	Application	Refs
Substrates of controlled compliance	Measurement of cellular mechanosensing: testing of the role of microenvironment compliance on cellular functions	159,160
Substrates of controlled nanotopography	Testing the role of local topography on cell functions	161 – 163
Stretchable substrates	Measurement of subcellular and nuclear mechanotransduction	59,164
Biomimetic matrices	3D matrices of controlled pore size, compliance and distance between ligands	165
Adhesive micropatterns	Control of the dimensionality of the microenvironment (1D versus 2D); control of cell shape and size	20,131,132
Confining microchannels	Measurement of cell motility in confined spaces	166
Microfluidic devices	Control and measurement of cell chemotaxis and durotaxis; cell sorting; high-throughput molecular detection	61,167–170
<b>Imaging</b>		
Multiphoton laser scanning microscopy	Real-time imaging of individual cells and extracellular matrix <i>in vivo</i>	31,73, 171,172
Fluorescence recovery after photobleaching (FRAP)	Measurement of the subcellular diffusion of molecules	173,174
Fluorescence loss in photobleaching (FLIP)	Measurement of the net transport of molecules in the cytoplasm	123,173,174
Fluorescence resonance energy transfer (FRET)	Protein localization and activity in live cells	175,176
Fluorescence lifetime imaging (FLIM)	Fluorescence imaging in thick samples	177
Fluorescence correlation spectroscopy	Dynamics of molecules in live cells	178,179
Photoactivation	Activation of proteins; ultraresolution microscopy	180 – 182

1D, one-dimensional; 2D, two-dimensional; 3D, three-dimensional.